Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of the Lung 1Neoplasm Metastasis 1

Interventions

Ipilimumab 5Nivolumab 4pembrolizumab 3sargramostim 2fludarabine 2binimetinib 2aldesleukin 2Interleukin-2 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 2trametinib 1tebentafusp 1sotrastaurin 1montanide ISA 51 1incomplete Freund's adjuvant 1glembatumumab vedotin 1fludarabine phosphate 1entrectinib 1Valproic Acid 1Tramadol 1Thalidomide 1Temozolomide 1Solutions 1Ruthenium-106 1Radiotherapy 1RNA, Messenger 1Protein Kinase C 1Melphalan 1Magnetic Resonance Spectroscopy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × CR011-vcMMAE × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡